drugset
drugset / Trial / NCT04175925

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

NCT04175925 ↗

Phase 1 Completed 171 enrolled Bristol-Myers Squibb
RandomizedSequentialQuadruple-blindTreatment

Summary

A Study assessing the drug levels and drug effects of variable doses of BMS-986322 in Healthy Participants compared to a placebo. The study also assesses how BMS-986322 affects the body with food and its acidity levels.

Timeline

Start
2019-11-15
Primary completion
2021-07-13
Completion
2021-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject LOMECITINIB Small molecule — Oral
Background Famotidine Other / unclassified — —

Indications

No indication recorded.